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multiple diagnoses and the evolution of different potential
pain generators over time can make obtaining the correct
etiology, such as spinal stenosis, primary hip pathology, or
sacral fractures, a significant challenge.
Conclusions: When evaluating the chief complaint of low
back pain and extremity pain in the elderly stenotic patient,
one must explore all diagnostic entities and continuously
remember the vast differential diagnosis. If treatment is un-
successful, reassessment and consideration of alternative di-
agnoses is essential.
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Patients or Programs: A 7-year-old boy with thalamic
pain syndrome from an inoperable brain tumor.
Program Description: The patient was diagnosed with a
teratoid/rhabdoid brain tumor involving the right superior
brainstem and thalamus. He developed severe pain in his left
hand, which progressed to involve his left forearm. He had
been treated with simultaneous long-acting oxycodone, nor-
triptyline, and gabapentin, with little relief. On physical
examination he had a mildly increased tone in his left upper
extremity as well as hyperalgesia and allodynia. Oxycodone,
nortriptyline, and gabapentin were discontinued, and he was
started on oral baclofen 10 mg at bed time, primarily for pain
control. The patient had significant improvement in his pain,
with even occasional total resolution of pain. Pain resumed
after baclofen was stopped during a hospitalization. Resump-
tion of baclofen again markedly improved pain control.
Setting: University outpatient and inpatient settings.
Results: Significant decrease in pain while on oral baclofen,
worsening when baclofen discontinued.
Discussion: Central pain syndromes are neurologic condi-
tions caused by damage to or dysfunction of the central
nervous system, in this case thalamic in origin. Thalamic pain
syndrome is commonly treated with tricyclic antidepressants
or anticonvulsants. Baclofen is a -aminobutyric acid B
(GABA-B) agonist that is commonly used to treat spasticity
associated with upper motor neuron syndrome. GABA plays
numerous roles in the central nervous system and is thought
to play an important role in anti-nociception. Anti-nocicep-
tive effects of baclofen have been demonstrated, with most
evidence surrounding the treatment of trigeminal neuralgia
and pain associated with spinal lesions. This case developed
into an inadvertent A-B-A trial, with marked pain relief from
baclofen.
Conclusions: Baclofen may have a role in decreasing pain
in patients with thalamic pain syndrome.
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Objective: Recent studies have documented an associa-
tion between childhood obesity and hypertension with pre-
mature adult mortality. This study reports frequency of high
blood pressure (BP) and obesity in ambulatory children and
adolescents with cerebral palsy (CP), and explores their
relationship to each other and to severity of motor function.
Design: Cross-sectional.
Setting: 5 clinic sites in the United States and Canada.
Participants: N87 (43M, 24F), a subset of 112 partici-
pants used in a feasibility study for the multicenter Cerebral
Palsy Outcomes Project (CPOP). Participants were aged 6-17
years and had a diagnosis of CP, with motor function rated
level I-III with the Gross Motor Functional Classification
System (GMFCS).
Main Outcome Measures: Measures included weight,
height, and BP. Gender and age-specific BMI percentiles were
calculated and categorized as underweight, healthy weight,
overweight, or obese by using parameters from the CDC. BP
percentiles were determined by using BP readings and height
percentiles from the CDC. Hypertension was defined by
criteria of the National High Blood Pressure Education
Program.
Results: Gender (M:F1.5:1) and race/ethnicity were
similar to published reports on CP and with U.S. Census
Bureau statistics. Participants in the 3 GMFCS levels did
not differ by age (mean, 10.83.6 y), gender, race/ethnic-
ity, socioeconomic status, or BMI percentile. Approxi-
mately 30% of participants were overweight or obese
(85th BMI percentile) based on gender and age norms
for typically developing children. Abnormally high sys-
tolic (S) BP was found in approximately 23% of the
participants and in 20% for diastolic (D) BP. Neither SBP
nor DBP were associated with gender, age, or BMI percen-
tile, but both had a positive linear association with GM-
FCS.
Conclusions: An unexpectedly high frequency of 2 major
cardiovascular risk factors in ambulatory children with CP
was found. Notably, these BMI data might underestimate risk
because of low lean body mass in CP. Further study on a
larger population is needed. Future studies will be strength-
ened by designs that ensure accurate, reproducible measure-
ments, and compliance with measurement protocols in
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